The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Exdensur depemokimab Additional monitoring | GlaxoSmithKline Trading Services Limited | Asthma; Nasal Polyps | 🇪🇺 EU 2026-02-12 | Order → |
| mNexspike COVID-19 mRNA vaccine Additional monitoring | Moderna Biotech Spain, S.L. | COVID-19 virus infection | 🇪🇺 EU 2026-02-12 | Order → |
| Myqorzo aficamten Additional monitoring | Cytokinetics (Ireland) Limited | Cardiomyopathy, Hypertrophic | 🇪🇺 EU 2026-02-12 | Order → |
| Gotenfia golimumab BiosimilarAdditional monitoring | Stada Arzneimittel AG | Arthritis, Rheumatoid; Arthritis, Juvenile; Arthritis, Psoriatic; Axial Spondyloarthritis; Non-Radiographic Axial Spondyloarthritis; Colitis, Ulcerative | 🇪🇺 EU 2026-02-10 | Order → |
| Ranluspec ranibizumab BiosimilarAdditional monitoring | Lupin Europe GmbH | Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetes Complications; Retinal Vein Occlusion; Choroidal Neovascularization | 🇪🇺 EU 2026-02-10 | Order → |
| Vykoura leucovorin calcium New formulation or manufacturer | Avyxa Holdings | 🇺🇸 US 2026-02-03 | Order → | |
| Air air | General Air Service & Supply Company | 🇺🇸 US 2026-02-02 | Order → | |
| Yuvezzi brimonidine tartrate, carbachol New dosage form | Visus | 🇺🇸 US 2026-01-28 | Order → | |
| Quiofic folic acid New dosage form | Solubiomix | 🇺🇸 US 2026-01-26 | Order → | |
| Avtozma tocilizumab-anoh Biosimilar | Celltrion Inc | 🇺🇸 US 2026-01-21 | Order → | |
| Aqneursa L-acetylleucine OrphanAdditional monitoring | Intrabio Ireland Limited | Niemann-Pick Disease, Type C | 🇪🇺 EU 2026-01-19 | Order → |
| Dawnzera donidalorsen Additional monitoring | Otsuka Pharmaceutical Netherlands B.V. | Angioedemas, Hereditary | 🇪🇺 EU 2026-01-19 | Order → |
| Filkri filgrastim-laha Biosimilar | Accord Biopharma Inc. | 🇺🇸 US 2026-01-15 | Order → | |
| Zycubo copper histidinate New molecular entityPriority review | Sentynl Theraps Inc | 🇺🇸 US 2026-01-12 | Order → | |
| Inluriyo imlunestrant Additional monitoring | Eli Lilly Nederland B.V. | Breast Neoplasms | 🇪🇺 EU 2026-01-09 | Order → |
| Ondibta insulin glargine BiosimilarAdditional monitoring | Sandoz GmbH | Diabetes Mellitus | 🇪🇺 EU 2026-01-09 | Order → |
| VacPertagen pertussis vaccine (recombinant, acellular, component, adsorbed) | BioNet Europe | Whooping Cough; Infections | 🇪🇺 EU 2026-01-09 | Order → |
| Waskyra etuvetidigene autotemcel OrphanATMPAdditional monitoring | Fondazione Telethon ETS | Wiskott-Aldrich Syndrome | 🇪🇺 EU 2026-01-09 | Order → |
| Austedo deutetrabenazine Additional monitoring | Teva GmbH | Tardive Dyskinesia | 🇪🇺 EU 2026-01-08 | Order → |
| GalenVita germanium (68Ge) chloride;gallium (68Ga) chloride | Curium Romania S.R.L. | Radionuclide Imaging | 🇪🇺 EU 2026-01-08 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.